Development of an Imaging Technique for Boron Neutron Capture Therapy
The development of 4-<sup>10</sup>B-borono-2-<sup>18</sup>F-fluoro-L-phenylalanine (<sup>18</sup>FBPA) for use in positron emission tomography (PET) has contributed to the progress of boron neutron capture therapy (BNCT). <sup>18</sup>FBPA has shown si...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/10/8/2135 |
| _version_ | 1827685602502377472 |
|---|---|
| author | Nobuyoshi Fukumitsu Yoshitaka Matsumoto |
| author_facet | Nobuyoshi Fukumitsu Yoshitaka Matsumoto |
| author_sort | Nobuyoshi Fukumitsu |
| collection | DOAJ |
| description | The development of 4-<sup>10</sup>B-borono-2-<sup>18</sup>F-fluoro-L-phenylalanine (<sup>18</sup>FBPA) for use in positron emission tomography (PET) has contributed to the progress of boron neutron capture therapy (BNCT). <sup>18</sup>FBPA has shown similar pharmacokinetics and distribution to 4-<sup>10</sup>B-borono-L-phenylalanine (BPA) under various conditions in many animal studies. <sup>18</sup>FBPA PET is useful for treatment indication. A higher <sup>18</sup>FBPA accumulation ratio of the tumor to the surrounding normal tissue (T/N ratio) indicates that a superior treatment effect is expected. In clinical settings, a T/N ratio of higher than 2.5 or 3 is often used for patient selection. Moreover, <sup>18</sup>FBPA PET is useful for predicting the <sup>10</sup>B concentration delivered to the tumor and surrounding normal tissues, enabling high-precision treatment planning. Precise dose prediction using <sup>18</sup>FBPA PET data has greatly improved the treatment accuracy of BNCT. However, the methodology used for the data analysis of <sup>18</sup>FBPA PET findings varies; thus, data should be evaluated using a consistent methodology so as to be more reliable. In addition to PET applications, the development of <sup>18</sup>FBPA as a contrast agent for magnetic resonance imaging that combines gadolinium and <sup>10</sup>B is also in progress. |
| first_indexed | 2024-03-10T08:55:55Z |
| format | Article |
| id | doaj.art-d0b84bb090474125afe0582a243a0183 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T08:55:55Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-d0b84bb090474125afe0582a243a01832023-11-22T07:12:15ZengMDPI AGCells2073-44092021-08-01108213510.3390/cells10082135Development of an Imaging Technique for Boron Neutron Capture TherapyNobuyoshi Fukumitsu0Yoshitaka Matsumoto1Kobe Proton Center, Department of Radiation Oncology, Kobe 650-0047, Hyōgo, JapanDepartment of Radiation Oncology, Clinical Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Ibaraki, JapanThe development of 4-<sup>10</sup>B-borono-2-<sup>18</sup>F-fluoro-L-phenylalanine (<sup>18</sup>FBPA) for use in positron emission tomography (PET) has contributed to the progress of boron neutron capture therapy (BNCT). <sup>18</sup>FBPA has shown similar pharmacokinetics and distribution to 4-<sup>10</sup>B-borono-L-phenylalanine (BPA) under various conditions in many animal studies. <sup>18</sup>FBPA PET is useful for treatment indication. A higher <sup>18</sup>FBPA accumulation ratio of the tumor to the surrounding normal tissue (T/N ratio) indicates that a superior treatment effect is expected. In clinical settings, a T/N ratio of higher than 2.5 or 3 is often used for patient selection. Moreover, <sup>18</sup>FBPA PET is useful for predicting the <sup>10</sup>B concentration delivered to the tumor and surrounding normal tissues, enabling high-precision treatment planning. Precise dose prediction using <sup>18</sup>FBPA PET data has greatly improved the treatment accuracy of BNCT. However, the methodology used for the data analysis of <sup>18</sup>FBPA PET findings varies; thus, data should be evaluated using a consistent methodology so as to be more reliable. In addition to PET applications, the development of <sup>18</sup>FBPA as a contrast agent for magnetic resonance imaging that combines gadolinium and <sup>10</sup>B is also in progress.https://www.mdpi.com/2073-4409/10/8/2135BNCT<sup>18</sup>FBPAPET |
| spellingShingle | Nobuyoshi Fukumitsu Yoshitaka Matsumoto Development of an Imaging Technique for Boron Neutron Capture Therapy Cells BNCT <sup>18</sup>FBPA PET |
| title | Development of an Imaging Technique for Boron Neutron Capture Therapy |
| title_full | Development of an Imaging Technique for Boron Neutron Capture Therapy |
| title_fullStr | Development of an Imaging Technique for Boron Neutron Capture Therapy |
| title_full_unstemmed | Development of an Imaging Technique for Boron Neutron Capture Therapy |
| title_short | Development of an Imaging Technique for Boron Neutron Capture Therapy |
| title_sort | development of an imaging technique for boron neutron capture therapy |
| topic | BNCT <sup>18</sup>FBPA PET |
| url | https://www.mdpi.com/2073-4409/10/8/2135 |
| work_keys_str_mv | AT nobuyoshifukumitsu developmentofanimagingtechniqueforboronneutroncapturetherapy AT yoshitakamatsumoto developmentofanimagingtechniqueforboronneutroncapturetherapy |